|Table of Contents|

The higher expression of miR-34b is associated with increased sensitivity of HCC827 cells to Icotinib

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 05
Page:
676-680
Research Field:
Publishing date:

Info

Title:
The higher expression of miR-34b is associated with increased sensitivity of HCC827 cells to Icotinib
Author(s):
Zhai Yang; Liao Zijun; Wang Yuzhen; Zhang Qian; Xu Rui; Zheng Qi; Li Xu; Zhou Jing
Tumor Hospital of Shaanxi Province,Shaanxi Xi'an 710061，China.
Keywords:
miR-34b; Icotinib; HCC827; c-MET
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2018.05.007
Abstract:
Objective：To discuss the effect of the increase of miR-34b on the sensitivity of HCC827 cells to Icotinib.Methods：According to the need，the experiment was divided into 4 groups：HCC827（control group），HCC827/miR-34b group，HCC827/Icotinib，and HCC827/miR-34b/Icotinib group.MTT assay and flow cytometry analysis were used to test the cell proliferation，apoptosis rate and cell cycle.Real-time PCR were used to detect c-MET mRNA levels.Western Blot was used to detect protein of c-MET.Results：Transfection of miR-34b can suppress the cell growth of HCC827 cells，and promote the apoptosis（P<0.05）.Up-regulated miR-34b expression increased the sensitivity of HCC827 cells to Icotinib，and the IC50 decreased apparently（P<0.05).The expression of c-MET mRNA and protein in cells of HCC827/miR-34b and HCC827/miR-34b/Icotinib group were down-regulated significantly (P<0.05).Conclusion：These results suggested that miR-34b can suppress the cell growth and promote the apoptosis.The higher expression of miR-34b are associated with increased sensitivity of HCC827 cells to Icotinib.It may be related to the down-regulates of c-MET．

References:

［1］Tie-Cheng Liu，Xin Jin，Yan Wang.Role of epidermal growth factor receptor in lung cancer and targeted therapies［J］.Am J Cancer Res，2017，7(2)：187-202.
［2］Anita Midha，Simon Dearden，Rose McCormack.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology：A systematic review and global map by ethnicity (mutMapII)［J］.Am J Cancer Res，2015，5(9)：2892-2911.
［3］Jun Wang，Baocheng Wang，Huili Chu，et al.Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations［J］.Onco Targets Ther，2016，9：3711-3726.
［4］Laura Paladini，Linda Fabris，Giulia Bottai，et al.Targeting microRNAs as key modulators of tumor immune response［J］.J Exp Clin Cancer Res，2016，35：103.
［5］Gloria Bertoli，Isabella Castiglioni.MicroRNAs：New biomarkers for diagnosis，prognosis，therapy prediction and therapeutic tools for breast cancer［J］.Theranostics，2015，5(10)：1122-1143.
［6］Marisa Shiina，Yutaka Hashimoto，Taku Kato，et al.Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and caucasians［J］.Oncotarget，2017，8(5)：8356-8368.
［7］Jianyong Xiao，Yingying Li，Wenyin Zhang，et al.MiR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22［J］.Onco Targets Ther，2016，9：1525-1534.
［8］Yunlong He，Luis F de Castro，Min Hwa Shin，et al.p53 loss increases the osteogenic differentiation of bmscs［J］.Stem Cells，2015，33(4)：1304-1319.
［9］Yukiharu Hiyoshi，Aaron J Schetter，Hirokazu Okayama，et al.Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer［J］.Harris PLoS One，2015，10(4)：e0124899.
［10］I Garcia-Martínez，C Sánchez-Mora，M Pagerols，et al.Preliminary evidence for association of genetic variants in pri-miR-34b/c and abnormal miR-34c expression with attention deficit and hyperactivity disorder［J］.Transl Psychiatry，2016，6(8)：e87.
［11］Hong-Fei Gao，Jin-Ji Yang，Zhi-Hong Chen，et al.Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer［J］.Oncotarget，2016，7(26)：39535-39543.
［12］Qing-yong Chen，De-min Jiao，Yu-quan Wu，et al.MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small celllung cancer via c-Met/PI3k/Akt/mTOR pathway［J］.Oncotarget，2016，7(14)：1824.
［13］Matteo Brighenti.MicroRNA and MET in lung cancer［J］.Ann Transl Med，2015，3(5)：68.
［14］Jun Wang，Jianpeng Chen，Yan Guo.Strategies targeting angiogenesis in advanced non-small cell lung cancer［J］.Oncotarget，2017，8(32)：53854-53872.
［15］Robert M Jotte.Advances in molecular-based personalized non-small-cell lung cancer therapy：Targeting epidermal growth factor receptor and mechanisms of resistance［J］.Cancer Med，2015，4(11)：1621-1632.

Memo

Memo:
-
Last Update: 1900-01-01